Eurofins announces acquisition of all assets of Gomti Life Sciences
Eurofins, through Eurofins Advinus, acquires all assets of Gomti Life Sciences Private Limited through a business transfer agreement.
- Country:
- India
Bengaluru (Karnataka) [India], Feb 6 (ANI/BusinessWire India): Eurofins, through Eurofins Advinus, acquires all assets of Gomti Life Sciences Private Limited through a business transfer agreement. The assets include a fully equipped state-of-the-art manufacturing facility located in Bidadi Industrial Area, Bengaluru, India, with cGMP pilot plant, intermediate area and ISO class eight clean rooms and a total reactor capacity of about 45 KL.
With this acquisition, Eurofins Advinus will be able to manufacture RSMs, intermediates, APIs and NCEs. The company can now support drug substance requirements from multi-kilogram to MT scale for Toxicology studies, clinical trials and launch quantities. "This acquisition could be a game-changer for Eurofins Advinus as it enables the group to enter clinical development and commercial supply part of the Pharma R&D value chain through cGMP API supplies of NCEs. This addition is also a part of a larger foray of the Eurofins group into CDMO / CRAMS market," commented Rajiv Malik, MD of Eurofins Advinus Limited.
This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)
ALSO READ
-
Japanese Lawmakers Visit India to See Worker Protection and Skills Projects in Action
-
Indian Unions Push for Fair Recruitment and Rights for Care Workers in Germany
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
India's Delicate Balancing Act: Navigating Energy Security Amid Middle Eastern Tensions
Google News